Polycystic Ovary Syndrome

Overview & Definition

Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder of reproductive-age women, affecting approximately 5 to 10% of this population worldwide, and the leading cause of anovulatory infertility.[6][7] It is a heterogeneous, multisystem syndrome — not simply a "cyst" problem — defined by a combination of ovulatory dysfunction, androgen excess and a characteristic ovarian morphology. The polycystic ovary is a sign, not a diagnosis in itself: 20 to 30% of regularly cycling women have polycystic ovarian morphology (PCOM) on ultrasound without the syndrome, while a symptomatic woman with normal-appearing ovaries can still have PCOS.[6]

Three diagnostic frameworks are in active use, all of which mandate that other causes of hyperandrogenism or anovulation have been excluded first:[1][5]

The contemporary consensus (2018 and 2023 International Evidence-based Guidelines) endorses Rotterdam as the diagnostic standard for adults, while emphasising the exclusion of mimics (congenital adrenal hyperplasia, hyperprolactinaemia, thyroid disease, Cushing syndrome, androgen-secreting tumours) before the label is applied.[3][12]

Classification — Rotterdam Phenotypes

Once the diagnosis is made, the patient is classified into one of four Rotterdam phenotypes. Phenotype matters because it predicts metabolic severity and guides surveillance intensity.[1][12]

Phenotypes A and B (classic PCOS) carry the highest prevalence of obesity, insulin resistance, dyslipidaemia and metabolic syndrome; phenotype C is intermediate; phenotype D carries the lowest cardiometabolic burden but still requires cycle control and endometrial protection.[12]

Epidemiology & Risk Factors

PCOS begins at puberty (perimenarche) and persists across the reproductive lifespan, although menstrual cycles often regularise as menopause approaches while the metabolic risk does not.[6] Risk factors include family history (sisters of affected women have a 30 to 50% chance; mothers carry a 24% prevalence), premature pubarche or adrenarche, low birth weight followed by rapid postnatal catch-up growth, early menarche, obesity (which both exacerbates and unmasks insulin resistance), and a personal or family history of type 2 diabetes.[7][9]

The heritability is estimated at around 70%, but the inheritance is not Mendelian: it is polygenic, with over 20 replicated susceptibility loci (DENND1A, THADA, LHCGR, FSHB, TOX3, YAP1, RAD50, GATA4, INS-VNTR among the best characterised). Many of these loci overlap with type 2 diabetes and metabolic syndrome susceptibility, reinforcing the metabolic core of the syndrome.[6]

Pathophysiology

PCOS is best understood as a self-perpetuating triad: disordered gonadotropin regulation, insulin resistance with hyperinsulinaemia, and ovarian androgen excess. Each element amplifies the others, generating the vicious cycle that maintains the phenotype.[4][6]

1. Neuroendocrine abnormality — gonadotropin dysregulation

In PCOS the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator is accelerated, favouring pituitary luteinising hormone (LH) secretion over follicle-stimulating hormone (FSH). LH pulse amplitude and frequency are increased, FSH is relatively low or normal, producing the characteristic LH:FSH ratio over 2:1 to 3:1 (although the 2023 Guideline downgrades LH/FSH ratio to a supportive rather than diagnostic marker, since sensitivity is only around 60%).[3] Elevated LH tonically stimulates the ovarian theca interna cells to overproduce androstenedione and testosterone; relative FSH deficiency impairs the granulosa-cell aromatisation of these androgens to oestradiol, and impairs follicular maturation.

2. Insulin resistance and hyperinsulinaemia

Insulin resistance is present in 70 to 80% of women with PCOS (95% of obese, 60 to 70% of lean phenotypes) and is independent of obesity — that is, a PCOS-specific defect in insulin signalling (post-receptor, with serine rather than tyrosine phosphorylation of the insulin receptor).[4][7] The result is compensatory hyperinsulinaemia, which has three downstream effects:

1. Direct ovarian stimulation: insulin synergises with LH to upregulate CYP17A1 (17,20-lyase) activity in theca cells, increasing ovarian androgen synthesis.
2. Hepatic SHBG suppression: insulin inhibits hepatic sex-hormone-binding globulin synthesis in a dose-dependent manner; SHBG falls, raising the free androgen index (total testosterone divided by SHBG) even when total testosterone is only mildly elevated.
3. Reduced IGF-1 binding protein: free insulin-like growth factor-1 rises, further stimulating theca-cell androgen production. [1]

Insulin resistance is also the bridge to the metabolic phenotype: the patient develops dyslipidaemia (low HDL, high triglycerides), impaired glucose tolerance, hypertension and central adiposity, comprising the metabolic syndrome. [1]

3. Androgen excess and follicular arrest

Hyperandrogenaemia — compounded by reduced SHBG — exerts the follicular-arrest phenotype: an exaggerated cohort of pre-antral follicles is recruited, but selection of the dominant follicle fails, producing the "necklace" of 12 or more peripheral follicles (2 to 9mm) on ultrasound and an enlarged, stroma-rich ovary. Failure of ovulation produces unopposed oestrogen (from peripheral aromatisation of androstenedione to oestrone in adipose tissue), which drives endometrial proliferation, hyperplasia and, over time, carcinoma.[8]

4. Low-grade chronic inflammation and HPA-axis dysfunction

Women with PCOS have elevated CRP, IL-6, TNF-alpha and white-cell counts independent of obesity, suggesting a state of low-grade chronic inflammation that amplifies insulin resistance and ovarian androgen production.[6] A subset also show mild HPA-axis activation with mildly elevated cortisol, though this does not reach Cushing thresholds.

5. Genetic and developmental programming

The polygenic background is described above. A provocative developmental hypothesis suggests antenatal androgen exposure programs the PCOS phenotype in the next generation: female fetuses exposed to high androgen in utero develop a PCOS-like phenotype in adulthood, with transmitted epigenetic marks.[6]

Clinical Presentation

PCOS presents across a spectrum that mixes reproductive, androgenic, metabolic and psychological features. The tempo is chronic, beginning at puberty, but decompensation — virilisation, severe obesity, infertility — brings the patient to medical attention in the late teens to early 30s.[4]

The Ferriman-Gallwey (mFG) score

The modified Ferriman-Gallwey score grades terminal (androgen-responsive) hair growth on nine body sites: upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, upper arms, and thighs. Each site is scored 0 (no terminal hair) to 4 (frankly male pattern), for a maximum of 36.[3][12] The diagnostic threshold for hirsutism is ethnicity-dependent:

Atypical presentations examiners test deliberately

• Adolescent PCOS — irregular cycles are normal for 2 years post-menarche; do not diagnose PCOS on ultrasound alone within 8 years of menarche (PCOM is over-diagnosed in adolescents). The 2018 Guideline requires all three Rotterdam features in this group.[12]
• Lean PCOS — BMI under 25 but insulin resistance, hirsutism, infertility still present; common in South Asian populations; the metabolic burden is under-recognised.[9]
• Ovulatory PCOS (phenotype C) — regular cycles, hirsutism and PCOM; often missed because the GP attributes the hirsutism to constitutional causes.
• Post-pill PCOS — menstrual irregularity emerging after stopping the COCP is sometimes labelled PCOS, but the syndrome must fulfil Rotterdam criteria; the COCP may simply have masked pre-existing PCOS.
• Pregnancy and postpartum — fertility-treatment pregnancies carry higher rates of gestational diabetes and pre-eclampsia (see Special Populations).

Differential Diagnosis

Hyperandrogenism and anovulation have a wide differential. PCOS is a diagnosis of exclusion — every patient must be screened for the mimics below before the label is assigned.[4][11]

The single most important "rule-out" test is a morning 17-hydroxyprogesterone to exclude non-classic CAH, followed by TSH, prolactin, cortisol (if clinical features suggest Cushing) and DHEAS (if adrenal tumour suspected).[11]

Clinical & Bedside Assessment

The focused PCOS examination has four objectives: (a) document hyperandrogenism, (b) grade insulin resistance clinically, (c) screen the metabolic syndrome, and (d) exclude mimics.[4]

Bedside examination: [1]

• Anthropometry: weight, height, BMI, waist circumference (over 80cm in women = central obesity, South Asian cut-off).
• Blood pressure — hypertension accelerates the metabolic phenotype and is a target of therapy.
• Skin — score modified Ferriman-Gallwey (9 sites), inspect for acne (jawline, chest, back), acanthosis nigricans (nape of neck, axillae, groin, knuckles — a clinical marker of insulin resistance), skin tags, striae (Cushing screen).
• Hair — male-pattern temporal/vertex alopecia.
• Pelvic examination — clitoromegaly (virilisation marker; if present, exclude tumour), ovarian enlargement (rarely palpable; bimanual in virginal patients avoided).
• Breast examination — galactorrhoea (hyperprolactinaemia).
• General — moon facies, proximal muscle weakness, central fat distribution (Cushing screen). [1]

Investigations

The investigation strategy is structured into three tiers: confirm the diagnostic criteria, exclude the mimics, and assess the metabolic phenotype.[3][11]

Tier 1 — Confirm diagnostic features

• Menstrual history + day 21 serum progesterone: progesterone under 3 ng/mL (under 10 nmol/L) on day 21 confirms anovulation in that cycle.
• Total testosterone (preferably morning, fasting, drawn in early follicular phase): mildly elevated (typically 1.5 to 2.5 nmol/L; over 5 nmol/L = exclude tumour). The 2023 Guideline uses high-quality liquid chromatography–mass spectrometry (LC-MS/MS) assays, and recommends free testosterone or calculated free androgen index as the most sensitive biochemical marker.[3]
• SHBG: low — the cause of the raised free androgen index. Free androgen index = (total testosterone divided by SHBG) times 100.
• Anti-Mullerian hormone (AMH): typically 2 to 4 times higher in PCOS; the 2023 Guideline allows AMH as a substitute marker for PCOM in adults (using validated cut-offs of AMH over 3.2 to 5.5 ng/mL depending on assay). It is not recommended in adolescents or as a fertility-prognosis tool.[3]
• Transvaginal ultrasound (TVUS): PCOM = 12 or more follicles (2 to 9mm) per ovary OR ovarian volume over 10mL (Rotterdam 2003). With high-frequency transducers (8MHz or higher), the threshold is updated to 20 or more follicles per ovary and/or ovarian volume of 10mL or more.[3] Only one ovary meeting criteria is sufficient. Note PCOM alone (without hyperandrogenism or ovulatory dysfunction) does not diagnose PCOS in adolescents within 8 years of menarche.

Tier 1b — Diagnostic accuracy and interpretation pitfalls

The 2023 Guideline emphasises assay quality and interpretation in context, because naïve use of single markers misclassifies many patients.[3]

• Total testosterone alone has low sensitivity (around 30 to 60%) in PCOS because levels overlap with the upper reference range; free testosterone or the calculated free androgen index (sensitivity 70 to 90%) is the preferred biochemical marker.[3] Use liquid chromatography–mass spectrometry (LC-MS/MS) if available — direct immunoassays overestimate testosterone at the low female range and are not comparable across laboratories.
• SHBG is suppressed by insulin, androgens, glucocorticoids, hypothyroidism and growth hormone; it is raised by the COCP, pregnancy and hyperthyroidism. Always interpret the free androgen index in the light of current medications.
• 17-Hydroxyprogesterone is falsely elevated in the luteal phase or in pregnancy — draw it in the early follicular phase (day 3 to 5), in the morning, fasting.[11] A borderline result (2 to 6 nmol/L) requires an ACTH stimulation test (250 microg Synacthen IV, measure 17-OHP at 0 and 60 min); a stimulated peak over 30 to 65 nmol/L confirms non-classic CAH.
• Transvaginal ultrasound has limited utility in obese women (poor visualisation) and in adolescents within 8 years of menarche (PCOM is physiologic). The 2023 Guideline does not require ultrasound if both oligo/anovulation and hyperandrogenism are already documented — a clinical diagnosis is acceptable.[3]
• Anti-Mullerian hormone is age-dependent, falling from 25 to 35 years. The cut-off (over 3.2 to 5.5 ng/mL) is assay-specific and should be used cautiously in women over 35. AMH does not predict natural fertility, time to menopause, or response to ovulation induction in PCOS.[3]

Tier 2 — Exclude mimics

• 17-Hydroxyprogesterone (17-OHP): morning sample, follicular phase (day 3 to 5). Baseline over 6 nmol/L (200 ng/dL) suggests non-classic CAH; confirm with ACTH stimulation (Synacthen) test and genotype for CYP21A2.[11]
• TSH: exclude thyroid disease in every PCOS work-up.
• Prolactin: exclude hyperprolactinaemia (false-positive with macroprolactin — request PEG precipitation if discordant).
• DHEAS: adrenal androgen marker. Levels over 700 microg/dL (around 18.5 micromol/L) suggest an adrenal tumour.
• Overnight dexamethasone suppression test or 24-hr urinary free cortisol or late-night salivary cortisol: only if clinical features of Cushing.
• IGF-1 / oral glucose tolerance test for GH: only if acromegaly features.

Tier 3 — Metabolic assessment (annual, lifelong)

• Fasting glucose + fasting insulin or HOMA-IR — screen for insulin resistance and prediabetes.
• Oral glucose tolerance test (75g, 2-hour) — recommended at baseline, then every 1 to 3 years (more frequently if obese, gaining weight, or with first-degree family history of T2DM).[12]
• HbA1c — annual; cut-off 5.7% defines prediabetes, 6.5% defines diabetes.
• Lipid profile — total cholesterol, LDL, HDL (typically low), triglycerides (typically high), every 1 to 2 years.
• AST, ALT — screen for non-alcoholic fatty liver disease (NAFLD), present in 30 to 60% of PCOS.
• Endometrial biopsy (Pipelle) — if cycles are over 90 days apart, prolonged amenorrhoea, or abnormal uterine bleeding, to exclude endometrial hyperplasia or carcinoma (around 3x risk); hysteroscopy and directed biopsy if Pipelle non-diagnostic.[8]
• Sleep study (polysomnography) — if symptoms of obstructive sleep apnoea (snoring, witnessed apnoea, daytime sleepiness).

Management — Resuscitation

PCOS is not a medical emergency; the resuscitation domain is essentially one of recognising and managing the acute, severe, life-altering decompensations that can complicate its course. Two situations deserve specific mention: [1]

1. Severe metabolic decompensation — a previously undiagnosed PCOS patient may present in diabetic ketoacidosis or hyperosmolar hyperglycaemic state as the first manifestation of unrecognised type 2 diabetes. Manage with the standard DKA/HHS protocol (IV fluids, IV insulin, electrolyte replacement), and treat the underlying PCOS subsequently.
2. Suspected androgen-secreting tumour — sudden, severe virilisation (clitoromegaly, voice deepening, male-pattern baldness over months) with total testosterone over 5 nmol/L or DHEAS over 700 microg/dL is a "red-flag" requiring urgent imaging (pelvic ultrasound, adrenal CT or MRI) and surgical referral.[11]

Otherwise, management is ambulatory, chronic, and stratified by the patient's presenting complaint. [1]

Management — Definitive & Stepwise

PCOS management is symptom-targeted, because the syndrome has no cure. The 2023 International Evidence-based Guideline organises therapy by indication: lifestyle, menstrual irregularity/endometrial protection, hirsutism/acne, insulin resistance/metabolic features, fertility, and psychological wellbeing.[3]

Step 1 — Lifestyle (first-line for ALL patients, every phenotype)

• Weight loss of 5 to 10% of body weight — restores spontaneous ovulation in 30 to 60%, reduces hirsutism, improves insulin sensitivity, lowers androgens, and is the single most cost-effective intervention.[12]
• Diet: hypocaloric (500 to 750 kcal/day deficit), Mediterranean-style, low glycaemic index, high fibre.
• Exercise: at least 150 minutes per week of moderate aerobic activity plus 2 sessions of resistance training; intensity matters more than modality.
• Behavioural: sleep, stress, smoking cessation, alcohol reduction.
• Bariatric surgery: consider in morbid obesity (BMI over 40, or over 35 with comorbidity) where medical therapy fails.

Step 2 — Menstrual cycle regulation and endometrial protection

• Combined oral contraceptive pill (COCP) — first-line. Regulates cycles, protects the endometrium from unopposed oestrogen (reduces endometrial cancer risk), treats acne and hirsutism, raises SHBG (lowering free testosterone).[3]
• Drug: choose a COCP with an anti-androgenic progestogen — 30 microg ethinylestradiol plus drospirenone 3mg (e.g. Yasmin) or cyproterone acetate 2mg (co-cyprindiol, e.g. Dianette), or 30 microg ethinylestradiol with desogestrel 150 microg (Marvelon) if anti-androgenic effect is not the priority.
• Alternative (when COCP is contraindicated) — cyclical oral progestogen: medroxyprogesterone acetate 5 to 10mg daily for 12 to 14 days every 1 to 3 months, or dydrogesterone 10mg daily for 12 to 14 days, to induce a withdrawal bleed and protect the endometrium.
• Withdrawal bleeding must occur at least every 3 months (90 days) — the 2023 Guideline emphasises this as the threshold for endometrial surveillance.[3]

Step 3 — Hirsutism and acne

• COCP alone first for 3 to 6 months before adding an anti-androgen.
• Cyproterone acetate 2mg (in co-cyprindiol) or up to 50 to 100mg daily on cycle days 1 to 10 — potent anti-androgen.
• Spironolactone 100 to 200mg daily in divided doses — aldosterone antagonist with anti-androgen effect (competes for the androgen receptor, reduces testosterone synthesis). Most widely used anti-androgen. Avoid pregnancy (feminisation of male fetus); use with reliable contraception (the COCP).
• Eflornithine 13.9% cream topically twice daily to the face — inhibits ornithine decarboxylase, slows hair growth. May be combined with laser/photoepilation.
• Cosmetic: laser photoepilation (best on dark hair, light skin), electrolysis, bleaching, waxing. Finasteride (5mg daily) is third-line; flutamide is hepatotoxic and should be avoided.[11]
• Acne: topical retinoids and benzoyl peroxide, oral antibiotics (doxycycline 100mg daily), or isotretinoin for severe nodulocystic disease — in addition to COCP.

Step 4 — Insulin sensitiser therapy (metformin)

• Metformin 500mg once daily, titrated weekly by 500mg to a target of 1500 to 2000mg daily (typically 1000mg twice daily or 500mg three times daily). Slow titration reduces gastrointestinal side effects; the modified-release formulation improves tolerability.[3]
• Indications: impaired glucose tolerance, type 2 diabetes, metabolic syndrome, adjunct to lifestyle for weight management, ovarian dysfunction not controlled by the COCP.
• Effects: improves insulin sensitivity and glycaemic control, modest weight loss, restores ovulation in some (live-birth benefit only as adjunct to fertility therapy), small reduction in androgens. Limited effect on hirsutism.
• Side effects: nausea, diarrhoea, abdominal cramps (titrate slowly); lactic acidosis is rare; long-term use reduces vitamin B12 (monitor annually on chronic therapy).
• Other insulin sensitisers: pioglitazone 15 to 30mg daily (limited by weight gain, fluid retention, fracture risk), GLP-1 receptor agonists (liraglutide, semaglutide) for obesity with PCOS, increasingly used.

Step 5 — Fertility (ovulation induction)

• Letrozole 2.5mg daily on cycle days 3 to 7 (or 2 to 6), increasing to 5mg and 7.5mg in subsequent cycles if no response — FIRST-LINE pharmacological ovulation induction for PCOS-related anovulatory infertility.[2][10] The PPCOS II randomised trial demonstrated live birth rate 27.5% with letrozole vs 19.1% with clomiphene, with higher ovulation and fewer multiple pregnancies. The Cochrane review (2022) confirms superiority in live birth and ovulation.[10] The 2023 International Guideline reaffirms letrozole as first-line.[3]
• Clomiphene citrate 50mg on days 2 to 6 (titrate to 100mg, 150mg) — selective oestrogen receptor modulator that blocks hypothalamic oestrogen feedback, raising FSH. Second-line; risk of multiple ovulation (8 to 10% twins), ovarian hyperstimulation, anti-oestrogenic effect on cervical mucus and endometrium. Limit to 6 cycles (cumulative ovarian cancer risk if prolonged).[2]
• Metformin — adjunct for women with BMI over 30 or impaired glucose tolerance; improves ovulation rate but has no live-birth benefit as monotherapy.[12]
• Gonadotrophins (recombinant FSH) — second-line if oral agents fail. Use a low-dose step-up protocol: start 37.5 to 50 IU subcutaneously daily from day 2 or 3, hold for 7 to 14 days, then increase by 50% increments only if no follicular response. Monitor with transvaginal ultrasound plus serum oestradiol every 1 to 3 days; cancel the cycle if more than 2 dominant follicles over 16mm develop or oestradiol exceeds 1000 pg/mL to prevent ovarian hyperstimulation syndrome (OHSS) and higher-order multiples. Trigger ovulation with hCG 5000 to 10000 IU when the lead follicle reaches 17 to 18mm. Live birth 15 to 25% per cycle; multiple pregnancy 5 to 10%; OHSS 1 to 5%.[12]
• Laparoscopic ovarian drilling (LOD) — second-line surgical alternative to gonadotrophins in clomiphene- or letrozole-resistant PCOS. Technique: 4 to 6 punctures per ovary with unipolar diathermy (40W for 4 seconds) or laser at 4mm depth; the physical destruction of androgen-producing theca-stroma reduces ovarian androgen output and normalises the LH:FSH ratio. Advantages: single procedure, no OHSS, no multiple-pregnancy risk, no intensive monitoring. Risks: adhesion formation (20 to 30%, mostly mild), reduction in ovarian reserve, theoretical risk of premature ovarian insufficiency. Reserve for women with normal pelvic anatomy who desire pregnancy and have failed oral induction.[13]
• In vitro fertilisation (IVF) — third-line when ovulation induction fails, or with coexisting tubal disease, severe male factor, or advanced maternal age. PCOS patients carry a 2 to 3 times higher risk of OHSS because of their exaggerated follicular cohort; mitigate with a GnRH antagonist protocol plus GnRH-agonist trigger (triptorelin 0.2mg) instead of hCG, a freeze-all strategy with elective single frozen embryo transfer, and co-prescription of metformin 1500 to 2000mg daily through stimulation. Live birth 25 to 35% per fresh transfer; cumulative up to 60 to 70% with frozen transfers.[3]
• Inositol (myo-inositol 2 to 4g daily, or combined with folic acid) — over-the-counter supplement with modest insulin-sensitising and ovulation-restoring effect; endorsed as adjunct in some guidelines.[3]

Step 6 — Long-term metabolic protection

• Statins (atorvastatin 20 to 40mg daily) for dyslipidaemia — modest reduction in LDL; small reduction in testosterone; not recommended in pregnancy.
• Antihypertensives as needed for blood pressure targets.
• Annual screening for type 2 diabetes (HbA1c and/or fasting glucose), lipids, blood pressure, weight.
• Bariatric surgery if BMI over 40 (or over 35 with metabolic comorbidity) and lifestyle plus pharmacotherapy fail. [1]

Specific Subtypes & Scenarios

• Adolescent PCOS — diagnosis requires all three Rotterdam features (not 2 of 3) within 8 years of menarche, because oligomenorrhoea and PCOM are common physiologically in early adolescence.[3] Avoid labelling a 14-year-old with irregular cycles as PCOS without full work-up. Treatment focuses on cycle control (COCP) and lifestyle; avoid fertility drugs. Metformin is reserved for impaired glucose tolerance.

• Lean PCOS (BMI under 25) — insulin resistance is still present in 60 to 70%; metformin and lifestyle remain effective; the metabolic burden is often under-recognised.

• Pregnancy in PCOS — see Special Populations below.

• Perimenopause and menopause — cycles often regularise as ovarian function declines, but metabolic risk persists and may worsen; continue annual diabetes and lipid screening, weight management, and consider hormone replacement therapy for vasomotor symptoms.[12]

Complications & Pitfalls

Classic pitfalls

• Diagnosing PCOS without excluding CAH — non-classic 21-hydroxylase deficiency occurs in 1 to 10% of hyperandrogenic women and is treated with glucocorticoids, not the COCP or letrozole. Always send 17-OH progesterone before committing to PCOS.[11]
• Treating hirsutism without the COCP — anti-androgens (spironolactone, cyproterone) must be given with reliable contraception; feminising effects on a male fetus make monotherapy in a sexually active, possibly fertile PCOS woman hazardous.
• Overusing clomiphene — over 6 cycles the cumulative ovarian cancer risk rises; switch to letrozole or gonadotrophins if pregnancy does not occur.[12]
• Missing the endometrium — long-standing amenorrhoea in PCOS silently produces endometrial hyperplasia and carcinoma; ensure withdrawal bleeding is induced at least every 90 days.[8]
• Ignoring pregnancy risk — OHSS, multiple pregnancy and GDM are all real; PCOS pregnancies are higher-risk.
• Dismissing psychological morbidity — depression, anxiety and eating disorders are common and independently impair quality of life; screen and refer.[3]

Prognosis & Disposition

PCOS is a chronic, lifelong condition with no cure, but it is highly manageable. Prognosis depends on phenotype, adiposity, insulin resistance, and adherence to lifestyle and surveillance.[6]

• Cycle and fertility: weight loss of 5 to 10% restores ovulation in 30 to 60%; letrozole achieves live birth in around 27.5% per cycle in PPCOS II; cumulative live birth after 5 cycles of letrozole can reach 60 to 70%.[2]
• Diabetes: 25 to 30% of women with PCOS develop impaired glucose tolerance by age 30; 8 to 15% develop type 2 diabetes by age 40. Annual screening and metformin for high-risk patients slows progression.[9]
• Endometrial cancer: 3x background risk (9x with obesity); protective effect of regular withdrawal bleeds and the COCP.[8]
• Quality of life: significant impairment from hirsutism, infertility and obesity; appropriate treatment restores it.
• Lifespan: PCOS does not shorten lifespan directly, but it accelerates cardiovascular and metabolic disease trajectories.

Disposition: PCOS is managed outpatient by the GP, gynaecologist, reproductive endocrinologist, or endocrinologist depending on the dominant complaint. Acute admission is reserved for OHSS, surgical complications (LOD, bariatric surgery), or decompensated metabolic emergencies. [1]

Special Populations

Adolescents

Diagnosis requires all three Rotterdam features within 8 years of menarche (because irregular cycles and PCOM are physiologically common). The 2018 Guideline and its 2023 update caution against over-diagnosis; use phenotype-based criteria and prefer the COCP for cycle control over diagnostic labels that stigmatise.[3] Metformin is reserved for impaired glucose tolerance, and lifestyle is paramount.

Pregnancy

PCOS pregnancies carry 2 to 3 times the risk of gestational diabetes (screen with OGTT at 16 to 18 weeks and again at 24 to 28 weeks), 2 to 3 times the risk of pre-eclampsia, 1.5 to 2 times the risk of preterm delivery, and a higher rate of miscarriage. Pre-conception optimisation (weight loss, glycaemic control, folic acid 400 microg daily, withdrawal of anti-androgens, statins, and teratogenic agents before pregnancy) is essential. Metformin may be continued through the first trimester in some women to reduce miscarriage risk, with shared decision-making.[3]

Perimenopausal and menopausal women

Menstrual cycles often regularise as ovarian function declines, but the metabolic phenotype persists and may worsen. Continue annual diabetes and lipid screening; address vasomotor symptoms with HRT (no contraindication from PCOS); reassess cardiovascular risk. [1]

Lean phenotype (BMI under 25)

Insulin resistance is still present in 60 to 70%; metabolic syndrome is less pronounced but not absent. Treatment principles are the same; letrozole and lifestyle are first-line. [1]

Evidence, Guidelines & Regional Differences

Exam Pearls & High-Yield Minutiae

Exam application bank (NEET-PG / INICET)

One-line answer

Polycystic ovary syndrome (PCOS) is a heterogeneous, lifelong reproductive and metabolic disorder of reproductive-age women characterised by ovulatory dysfunction, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology (PCOM), defined by the Rotterdam 2003 consensus as any two of those three features, after exclusion of other causes. Insulin resistance with compensatory hyperinsulinaemia is the central driver in 70 to 80% of patients, augmented by gonadotropin dysregulation (elevated LH:FSH ratio) and low-grade chronic inflammation. Presentation clusters around oligomenorrhoea or amenorrhoea, hirsutism (modified Ferriman-Gallwey score over 4 to 6), acne, central obesity, acanthosis nigricans, and anovulatory infertility. Management is stratified by the patient's presenting complaint: lifestyle (5 to 10% weight loss) for all; combined oral contraceptive pill (COCP)

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Polycystic Ovary Syndrome.

Summary

Polycystic ovary syndrome is a chronic, multisystem, reproductive-metabolic disorder that every generalist and gynaecologist will encounter repeatedly. Master the three diagnostic frameworks (Rotterdam, NIH, AE-PCOS), classify the phenotype, exclude the mimics with a focused biochemical panel, and treat the symptom in front of you — lifestyle for all, COCP for cycles and endometrium, anti-androgens for hirsutism, letrozole for fertility, metformin for insulin resistance. Above all, screen for life annually: HbA1c, lipids, blood pressure, mood, and (when amenorrhoea is prolonged) the endometrium. The PCOS patient is yours for life — make that life longer, healthier and more fertile by getting the basics right. [1]